創業慧康(300451.SZ):2017年第一期員工持股計劃出售完畢
格隆匯 6 月 24日丨創業慧康(300451.SZ)公佈,公司2017年第一期員工持股計劃已於2020年6月23日全部出售完畢,截至公告日,公司2017年第一期員工持股計劃證券賬户已於2020年6月23日通過集中競價方式減持了剩餘的約2.26萬股,至此2017年第一期員工持股計劃全部股份已通過2019年2次大宗交易、2020年1次集中競價的方式出售完畢,其中大宗交易的受讓方與公司5%以上股東、實際控制人不存在關聯關係或者一致行動關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.